Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EEC 2022 | Improving the effectiveness of ANT DBS therapy for refractory epilepsy

Jukka Peltola, MD, PhD, University Hospital of Tampere, Tampere University, Tampere, Finland, outlines ongoing efforts to maximize the efficacy of deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) for the treatment of drug-resistant epilepsy. Several studies have looked into the importance of contact location, finding in some cases that repositioning of contacts can improve responses. Dr Peltola also discusses alternative surgical techniques, such as using a lateral approach to avoid transventricular access. Individualized programming is also a work-in-progress, with some evidence to suggest that changes in DBS programming or repositioning of contacts may improve responses on an individual basis. This interview took place at the 14th European Epilepsy Congress (EEC) 2022 in Geneva, Switzerland.


Jukka Peltola reports the following disclosures:
-Medical Director and co-founder, Neuro Event Labs
-Research grants from Eisai, Livanova, Medtronics, Pfizer and UCB
-Speaker honoraria from Eisai, Livanova, Medtronics, Orion, Pfizer and UCB
-Support for travel to congresses from Eisai, Livanova, Medtronics and UCB
-Advisory boards of Arvelle, Bial, Eisai, GW-Pharma, Livanova, Medtronics, UCB